Celiac Disease Treatment Market Research Report - Global Forecast till 2030

Celiac Disease Treatment Market Research Report: By Treatment, By End-User (Hospitals and clinics, Clinical Research Organizations, Research & Academic Institutes) – Forecast to 2030

ID: MRFR/HC/7002-HCR | August 2022 | Region: Global | 110 Pages         

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

 

6. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY TREATMENT

6.1. Overview

6.2. Gluten-Free Diet

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.1 Gluten-Free Bakery Products

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Gluten-Free Baby Food

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3 Gluten-Free Pasta

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.4 Gluten-Free Meals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Vitamin and Mineral Supplements

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Medications

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.1 Azathioprine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.2 Budesonide

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

 

7. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY END USER

7.1. Overview

7.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Clinical Research Organizations

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL CELIAC DISEASE TREATMENT MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1.1. Overview

9.1.2. Competitive Analysis

10. COMPANY PROFILES

10.1. Amgen Inc. (US)

10.1.1. Company Overview

10.1.2. Type Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Amneal Pharmaceuticals LLC (US)

10.2.1. Company Overview

10.2.2. Type Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. BioLineRx (Israel)

10.3.1. Company Overview

10.3.2. Type Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Calypso Biotech SA (Switzerland)

10.4.1. Company Overview

10.4.2. Type Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Freedom Foods Group Limited (Australia)

10.5.1. Company Overview

10.5.2. Type Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. General Mills, Inc. (US)

10.6.1. Company Overview

10.6.2. Type Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Glenmark Pharmaceuticals Inc. (India)

10.7.1. Company Overview

10.7.2. Type Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Hain Celestial Group, Inc. (US)

10.8.1. Company Overview

10.8.2. Type Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Innovate Biopharmaceuticals Inc. (US)

10.9.1. Company Overview

10.9.2. Type Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Kellogg Company (US)

10.10.1. Company Overview

10.10.2. Type Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Mondelez International Inc. (US)

10.11.1. Company Overview

10.11.2. Type Overview

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Mylan Pharmaceuticals Inc. (US)

10.12.1. Company Overview

10.12.2. Type Overview

10.12.3. Financial Overview

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

 

10.13. Pinnacle Foods, Inc. (US)

10.13.1. Company Overview

10.13.2. Type Overview

10.13.3. Financial Overview

10.13.4. Key Developments

10.13.5. SWOT Analysis

10.13.6. Key Strategies

10.14. Selecta Biosciences, Inc (US)

10.14.1. Company Overview

10.14.2. Type Overview

10.14.3. Financial Overview

10.14.4. Key Developments

10.14.5. SWOT Analysis

10.14.6. Key Strategies

10.15. Takeda Pharmaceutical Company Ltd (Japan)

10.15.1. Company Overview

10.15.2. Type Overview

10.15.3. Financial Overview

10.15.4. Key Developments

10.15.5. SWOT Analysis

10.15.6. Key Strategies

10.16. The Kraft Heinz Company (US)

10.16.1. Company Overview

10.16.2. Type Overview

10.16.3. Financial Overview

10.16.4. Key Developments

10.16.5. SWOT Analysis

10.16.6. Key Strategies

10.17. West-Ward Pharmaceutical (US)

10.17.1. Company Overview

10.17.2. Type Overview

10.17.3. Financial Overview

10.17.4. Key Developments

10.17.5. SWOT Analysis

10.17.6. Key Strategies

10.18. Zedira GmbH (Germany)

10.18.1. Company Overview

10.18.2. Type Overview

10.18.3. Financial Overview

10.18.4. Key Developments

10.18.5. SWOT Analysis

10.18.6. Key Strategies

10.19. Zydus Pharmaceuticals Inc. (US)

10.19.1. Company Overview

10.19.2. Type Overview

10.19.3. Financial Overview

10.19.4. Key Developments

10.19.5. SWOT Analysis

10.19.6. Key Strategies

10.20. Others

11. APPENDIX

11.1. References

11.2. Related Reports

 

LIST OF TABLES

TABLE 1 GLOBAL CELIAC DISEASE TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL CELIAC DISEASE TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CELIAC DISEASE TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 6 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 US: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 US: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 CANADA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 11 CANADA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 LATIN AMERICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 13 LATIN AMERICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 17 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 18 EASTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 19 EASTERN EUROPE: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELIAC DISEASE TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELIAC DISEASE TREATMENT MARKET

FIGURE 4 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 5 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 6 GLOBAL CELIAC DISEASE TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7AMERICAS: CELIAC DISEASE TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 8 EUROPE: CELIAC DISEASE TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 WESTERN EUROPE: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 ASIA-PACIFIC: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 MIDDLE EAST & AFRICA: CELIAC DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 GLOBAL CELIAC DISEASE TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 AMGEN INC.: KEY FINANCIALS

FIGURE 14 AMGEN INC.: SEGMENTAL REVENUE

FIGURE 15 AMGEN INC.: REGIONAL REVENUE

FIGURE 16 AMNEAL PHARMACEUTICALS LLC: KEY FINANCIALS

FIGURE 17 AMNEAL PHARMACEUTICALS LLC: SEGMENTAL REVENUE

FIGURE 18 AMNEAL PHARMACEUTICALS LLC: REGIONAL REVENUE

FIGURE 19 BIOLINERX: KEY FINANCIALS

FIGURE 20 BIOLINERX: SEGMENTAL REVENUE

FIGURE 21 BIOLINERX: REGIONAL REVENUE

FIGURE 22 CALYPSO BIOTECH SA: KEY FINANCIALS

FIGURE 23 CALYPSO BIOTECH SA: SEGMENTAL REVENUE

FIGURE 24 CALYPSO BIOTECH SA: REGIONAL REVENUE

FIGURE 25 FREEDOM FOODS GROUP LIMITED: KEY FINANCIALS

FIGURE 26 FREEDOM FOODS GROUP LIMITED: SEGMENTAL REVENUE

FIGURE 27 FREEDOM FOODS GROUP LIMITED: REGIONAL REVENUE

FIGURE 28 GENERAL MILLS, INC.: KEY FINANCIALS

FIGURE 29 GENERAL MILLS, INC.: SEGMENTAL REVENUE

FIGURE 30 GENERAL MILLS, INC.: REGIONAL REVENUE

FIGURE 31 GLENMARK PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 32 GLENMARK PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 33 GLENMARK PHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 34 HAIN CELESTIAL GROUP, INC.: KEY FINANCIALS

FIGURE 35 HAIN CELESTIAL GROUP, INC.: SEGMENTAL REVENUE

FIGURE 36 HAIN CELESTIAL GROUP, INC.: REGIONAL REVENUE

FIGURE 37 INNOVATE BIOPHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 38 INNOVATE BIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 39 INNOVATE BIOPHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 40 KELLOGG COMPANY: KEY FINANCIALS

FIGURE 41 KELLOGG COMPANY: SEGMENTAL REVENUE

FIGURE 42 KELLOGG COMPANY: REGIONAL REVENUE

FIGURE 43 MONDELEZ INTERNATIONAL INC.: KEY FINANCIALS

FIGURE 44 MONDELEZ INTERNATIONAL INC.: SEGMENTAL REVENUE

FIGURE 45 MONDELEZ INTERNATIONAL INC.: REGIONAL REVENUE

FIGURE 46 MYLAN PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 47 MYLAN PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 48 MYLAN PHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 49 PINNACLE FOODS, INC.: KEY FINANCIALS

FIGURE 50 PINNACLE FOODS, INC.: SEGMENTAL REVENUE

FIGURE 51 PINNACLE FOODS, INC.: REGIONAL REVENUE

FIGURE 52 SELECTA BIOSCIENCES, INC: KEY FINANCIALS

FIGURE 53 SELECTA BIOSCIENCES, INC: SEGMENTAL REVENUE

FIGURE 54 SELECTA BIOSCIENCES, INC: REGIONAL REVENUE

FIGURE 55 TAKEDA PHARMACEUTICAL COMPANY LTD: KEY FINANCIALS

FIGURE 56 TAKEDA PHARMACEUTICAL COMPANY LTD: SEGMENTAL REVENUE

FIGURE 57 TAKEDA PHARMACEUTICAL COMPANY LTD: REGIONAL REVENUE

FIGURE 58 THE KRAFT HEINZ COMPANY: KEY FINANCIALS

FIGURE 59 THE KRAFT HEINZ COMPANY: SEGMENTAL REVENUE

FIGURE 60 THE KRAFT HEINZ COMPANY: REGIONAL REVENUE

FIGURE 61 WEST-WARD PHARMACEUTICAL: KEY FINANCIALS

FIGURE 62 WEST-WARD PHARMACEUTICAL: SEGMENTAL REVENUE

FIGURE 63 WEST-WARD PHARMACEUTICAL: REGIONAL REVENUE

FIGURE 64 ZEDIRA GMBH: KEY FINANCIALS

FIGURE 65 ZEDIRA GMBH: SEGMENTAL REVENUE

FIGURE 66 ZEDIRA GMBH: REGIONAL REVENUE

FIGURE 67 ZYDUS PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 68 ZYDUS PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 69 ZYDUS PHARMACEUTICALS INC.: REGIONAL REVENUE


Celiac Disease Treatment Market Speak to Analyst Request a Free Sample

Market Overview


The Celiac Disease Treatment Market is anticipated to have a significant growth with a 11.03% CAGR. Therefore, the market value will further increase up to USD 1,061.20 Million in the studied forecast period 2020-2030. Celiac disease is basically an auto-immune and genetic disorder. This disease damages the small intestine and causes various diseases such as neurological disorders, low bone density, infertility, and even cancers.


Several factors such as the penetration of therapeutic products among developing countries are empowering the Celiac Disease Treatment Market Growth. However, the growing awareness for healthcare and technological advancements will improve the market growth in this region. It is anticipated that the Asia-Pacific region will rise to significant CAGR during the studied forecast period.


COVID-19 Analysis


Governments across the world were highly affected due to the outbreak of the COVID-19 disease. It put a huge burden on the healthcare sector to treat the affected patients. Due to this reason, treatment of other diseases was highly affected. However, the development of vaccines and waiver of lockdown has helped the market to improve its growth. Along with that, the market players are investing to improve Celiac Disease Treatment Market Growth in the future years.


Market Dynamics


Market Drivers


Various drivers such as the rising use of therapeutic drugs, diseases like diabetes, and favorable policies by governments will boost the market. Additionally, the prevalence of junk and packaged foods, rising disposable income will further drive the Celiac Disease Treatment Market in the future years.


Restraints


The low availability of specialized treatment across various underdeveloped and developing countries can restraint the market growth. Also, low awareness and lack of skilled professionals for diagnosis can hamper the market growth significantly.


Opportunities


Various opportunities such as investments by the key players can offer new opportunities for the market. Acquisitions, collaborations, mergers, partnerships, etc. are anticipated to open new opportunities for the Celiac Disease Treatment Market.


Challenges


As of now, there is still no drug available for the treatment of celiac disease. Along with that, the misdiagnosis of the treatment can be a major challenge for the Celiac Disease Treatment Market Growth.


Cumulative Analysis


The Compound Annual Growth Rate (CAGR) of the Celiac Disease Treatment Market is estimated to touch 12%. Therefore, the market value will further increase up to USD 680.5 Million in the studied forecast period 2021-2028. The rising technological developments and improvement in the treatment of the disease will have a significant impact on the market.


Value Chain Analysis


The Celiac Disease Treatment Market Analysis suggests that the market will grow significantly in the upcoming years. The rising developments and several drivers such as increasing cases of diabetes and other neurological diseases will further increase the Celiac Disease Treatment Market Trends. Therefore, the value chain will improve in the forthcoming years.


Market Segmentations


The Celiac Disease Treatment Market Size is divided into various segments such as treatment, drugs, enzyme type, and end-user. On the basis of treatment, the market is fragmented into Immunosuppressive Drugs and Steroids, Therapeutic Vaccines, and Dietary and Vitamin Supplements.


On the basis of drugs, the Celiac Disease Treatment Market is segmented into Second-Line Treatment and First-Line Treatment.


On the basis of enzyme type, the Market is bifurcated into Gas, Bloating, Fatigue, Diarrhoea, Distension, and Others.


On the basis of end-user, the Market is segmented into Clinical Research Organisations, Clinics, and Hospitals, and Academic Institutes.


Regional Analysis


Regionally, the Celiac Disease Treatment Market Size is divided into Europe, Americas, Africa, and the Middle East, and Asia-Pacific. The Americas is expected to hold the largest share in the upcoming years. The rising cases of celiac diseases are one of the celiac diseases and the presence of various key players among the countries is pushing the market growth.


Secondly, Europe will have the second-largest Celiac Disease Treatment Market Share in the upcoming years. The increasing expenditure in the healthcare and presence of advanced healthcare infrastructure is evaluated to improve the market growth in the upcoming years.


Asia-Pacific region is anticipated to record the fastest growth in the future years. Mainly countries such as India, China are developing at a rapid speed. As a result, the market will have significant growth in the future years.


Africa and the Middle East region are evaluated to have the least share in the Celiac Disease Treatment MarketHence, various underdeveloped nations and low infrastructure are the major cause of the slow growth rate.


Competitive Landscape


The Celiac Disease Treatment Market is fragmented with the presence of various key players. These key players play a crucial role in elevating market growth. They do strategic developments such as acquisitions, partnerships, collaborations, new ventures, etc. Some of the key players in the market are as follows.



  • General Mills Inc. (US)

  • Hain Celestial Group Inc. (US)

  • Amgen Inc. (US)

  • Glenmark Pharmaceuticals Inc. (India)

  • Amneal Pharmaceuticals LLC (US)

  • Freedom Foods Group Limited (Australia)

  • Kellogg Company (US)

  • The Kraft Heinz Company (US)

  • Pinnacle Foods, Inc. (US)

  • Takeda Pharmaceuticals Company Ltd. (Japan)

  • Mondelez International Inc., (US)

  • West-Ward Pharmaceutical (US)

  • Calypso Biotech SA (Switzerland)

  • BioLineRx (Israel)

  • Zedira GmbH (Germany)

  • Innovative Biopharmaceuticals Inc. (US)

  • Mylan Pharmaceuticals Inc. (US)

  • Zydus Pharmaceuticals Inc. (US)


Recent Developments


No recent developments were found.


Report Overview


The overview of the Celiac Disease Treatment Market Outlook is listed below.



  • Market Overview

  • COVID-19 Analysis

  • Dynamics of the Market

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Analysis

  • Recent Development


Report Score and Segmentation


The report score of the Celiac Disease Treatment Market Forecast is to highlight information such as market CAGR value, opportunities, drivers, key players, recent development, etc. Furthermore, the information provided in this report is collected from various secondary and primary sources.



  • Study Period- 2021-2028

  • Base Year-2021

  • Forecast Period- 2021-2028

  • Historical Period-2017-2020


Segmentation


By Treatment



  • Immunosuppressive Drugs and Steroids

  • Therapeutic Vaccines

  • Dietary and Vitamin Supplements


By Drug



  • Second-Line Treatment

  • First-Line Treatment


By Enzyme Type



  • Gas

  • Bloating

  • Fatigue

  • Diarrhea

  • Distension

  • Others


End-User



  • Clinical Research Organisations

  • Clinics and Hospitals

  • Academic Institutes


By Region



  • Americas

  • Africa and the Middle East

  • Asia-Pacific

  • Europe



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 1061.20 Million
  CAGR   11.03% (2020-2030)
  Base Year   2019
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen Inc. (US), Amneal Pharmaceuticals LLC (US), BioLineRx (Israel), Calypso Biotech SA (Switzerland), Freedom Foods Group Limited (Australia), General Mills, Inc. (US), Glenmark Pharmaceuticals Inc. (India), Hain Celestial Group, Inc. (US), Innovate Biopharmaceuticals Inc. (US), Kellogg Company (US), Mondelez International Inc. (US), Mylan Pharmaceuticals Inc. (US), Pinnacle Foods, Inc. (US), Selecta Biosciences, Inc (US), Takeda Pharmaceutical Company Ltd (Japan), The Kraft Heinz Company (US), West-Ward Pharmaceutical (US), Zedira GmbH (Germany), Zydus Pharmaceuticals Inc. (US)
  Key Market Opportunities   Technology advances and research and development
  Key Market Drivers

  • Increasing number of clinical trials for drugs against celiac disease
  • Rising awareness for the diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Celiac Disease Treatment Market is projected to grow at an 11.03% CAGR between 2020-2030.

    The Americas is expected to dominate the Celiac Disease Treatment Market.

    Celiac Disease Treatment Market is predicted to touch USD 1061.20 million by 2030.

    Hospitals and clinics will lead the Celiac Disease Treatment Market.

    Gluten-free diet segment will dominate the Celiac Disease Treatment Market.